BioNTech is a publicly listed company tracked for investment-relevant business developments.
BioNTech (founded by immigrants) briefly reached $100B valuation, demonstrating Germany's potential in AI-enabled biotech; Klöckner argues Germany should build 10 more such companies leveraging its scientific talent.